Introduction
Improved lifestyle, together with more effective pharmacotherapy and invasive treatment, has resulted in a decline in first-time coronary artery disease (CAD) and increased survival in patients with established CAD. 1, 2 Despite the decline in mortality from CAD, it remains one of the leading causes of premature death on a European scale. 2 Aside from an additional risk of premature death, CAD is also associated with risk of recurrent cardiovascular events, e.g. stroke and recurrent myocardial infarction (MI), with the highest risk of it has become even more relevant to clarify the long-term risk of recurrent events in stable post-MI patients with distinct risk profiles. Thus, high-risk patients might benefit from extended tailored treatment approach. However, it is important to highlight the fact that a considerable proportion of patients with established illness still appear to receive sub-optimal cardiac care, 7 secondary prevention and cardiac rehabilitation. 8 Another serious challenge is that the prevalence of coexisting chronic illnesses, which in many cases share the same risk factors as CAD, 9 is high and increasing, 1 but even more importantly, are associated with unfavourable prognosis in patients with CAD. 1, [10] [11] [12] [13] [14] Although CAD severity is one of the strongest risk factors for long-term outcome, [15] [16] [17] [18] [19] [20] its importance in late-risk stratification and in relation to co-morbidity among stable post-MI patient who have stayed event-free on the first year is not entirely clear.
Recognizing that CAD extent and severity can been graded differently from the more simple usage of the number of stenosed vessels [15] [16] [17] to the use of more complex scoring system 21 and that the coronary angiography (CAG) lack of ability to detect prognostically important physiological stenosis, 22 we investigated the longterm (1 year and beyond) impact of CAD severity, using the simple estimation of CAD severity (no obstructive CAD, 1-, 2-, 3-vessel disease [VD] or left main stenosis [LMS] ), in relation to co-morbidity for recurrent events in a nationwide study population. Patients conservatively treated who were not receiving CAG, and thus with no information on CAD severity, were also included, as conservatively treated patients fare worse than invasively treated patients and deserve equal attention in terms of attaining knowledge of risk and risk factors.
Methods

Data sources
In Denmark, each resident has a unique and permanent identification number that enables individual-level linkage among several Danish nationwide administrative registries, allowing record linkage analysis. (i) The Civil Registrations System holds information on sex, year of birth, civil status and the unique identifier on each Danish resident since 1968. 23 (ii)
The Danish National Patient Registry (DNPR) holds information on dates of admission and discharge, main and secondary discharge diagnoses according to the International Classification of Diseases, 10th revision (ICD-10), from 1994, and surgical procedure codes according to the NOMESCO Classification of Surgical Procedures (NCSP) from 1996. Since 2002, the DNPR has used the Diagnosis-Related Group system for hospital reimbursement. 24 (iii) The Danish Register of Causes of Death keeps records on date and cause(s) of death classified according to ICD-10 since 1994. 25 (iv) The Danish Heart Registry (DHR) is a clinical quality database that keeps track on invasive examinations and treatments, which include CAG, percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) since 2000. In addition, risk factors such as diabetes mellitus (DM) are recorded as well. The DHR has national coverage on CAG since 2006. National coverage is defined as more than 89% of the produces recorded in the DHR as well as in the DNPR in relation to the number of procedures registered in the DNPR. Each hospital performing CAG, PCI, or CABG is obligated to report data on performed procedures to the DHR. 26 
Study population
We identified all patients > _18 years with first recorded primary or secondary diagnosis of index MI (ICD-10: I21) from 1 January 2004 to 31 December 2010, and who had no prior MI admissions registered in the previous 12 months (Figure 1 ). Patients with a recent MI history were not included, because they probably had a different risk profile per se and were most likely already in dual treatment and revascularized.
Myocardial infarction population
Patients who survived index MI, without stroke or recurrent MI within 7 days from discharge, were included. The quarantine period from index MI to 7 days after discharge, at which point all were alive, was chosen to allow assessment of medication at discharge. Co-morbidities, comprising prior MI, cerebrovascular disease, peripheral arterial disease, heart failure, arrhythmia, shock, pulmonary oedema, acute renal failure, chronic renal failure, DM, cancer, respiratory insufficiency, chronic obstructive pulmonary disease, anaemia, and infection, were defined as the presence of discharge diagnoses up to 10 years prior to the index MI, but prior MI was identified if any diagnosis since 1994. Identification of important comorbidities in an unselected MI population was based on the Ontario acute MI mortality prediction rules, 28 which was modified by expanding the time window for co-morbidity identification, identifying DM with as well as without complications and specifying additional co-morbidities of importance, including for type 2 MI. 29, 30 The incomplete capture of discharge code-based heart failure and DM was compensated by including loop diuretics and glucose-lowering drugs. Arrhythmia indicated cardiac arrest, paroxysmal tachycardia, atrial fibrillation/flutter, and other cardiac arrhythmias. Shock indicated cardiogenic, hypovolaemic, or other/unspecified shock. Infection indicated urinary tract infection and sepsis of bacterial or fungal origin. Revascularization was measured up to 7 days after hospital discharge. Concomitant medication was defined as redeemed prescriptions from 365 days before hospital admission until 7 days after discharge. Socioeconomic status was measured by means of 5-year average index income (in quintiles) and civil status (married, living with a partner or living alone).
Stable post-myocardial infarction population
For 'stable' post-MI patients, who survived the first 365 days after the index MI, without a stroke or recurrent MI, identification of comorbidities (discharge-as well as drug-based codes) was extended until 365 days after discharge. Revascularization was measured up to 365 days after hospital discharge. Concomitant medication (excluding loop diuretics and glucose-lowering drugs) was defined as redeemed prescriptions from day 244 to day 365 after discharge. Socioeconomic status was measured at index MI. A full list of the ICD-10, procedure (NCSP) and ATC codes used to identify co-morbidity, revascularization and medication is provided in the Supplementary material online, 
Coronary artery disease severity
Identification of CAD severity was based on the findings from CAG and PCI performed up to 7 and 365 days after hospital discharge for the index MI and stable post-MI population, respectively. CAD severity was defined according to the number of obstructive coronary arteries corresponding to 50% or more narrowing and categorized into 7 groups: no significant stenosis, 1-, 2-, 3-VD, LMS, missing angiographic data or if no CAG was performed. LMS with or without additional diseased vessels were categorized as LMS only. For patients with >1 angiography record, the record with the most severe disease was retained for the analysis. Multi-vessel CAD (MVD) was defined as 2-or 3-VD or LMS.
Endpoint and follow-up
The primary composite endpoint was defined as the first recorded primary or supplementary diagnosis of MI (ICD10: I21), ischemic stroke (ICD10: I63, I64) or fatal cardiovascular disease (CVD) (ICD10: I00-I99). MI or stroke was considered to be non-fatal regardless of subsequent death at a later point in time (i.e. > _1 day after non-fatal MI/stroke) and non-fatal MI or stroke appearing at the same time was classified as nonfatal MI. For the index MI patients, the length of follow-up was defined as the time elapsed from day 7 after hospital discharge until the primary composite endpoint, death, emigration, or end of 1-year follow-up (day 365 after discharge). For the stable post-MI patients, the length of followup was defined as the time elapsed from day 366 after hospital discharge until the primary composite endpoint, death, emigration, or end of study follow-up (31 December 2012).
Statistical methods
Continuous and categorical variables were presented as median (interquartile range) and as frequencies (%), respectively. Kruskal-Wallis test was used for comparison of continuous variables, whereas chi-square test was used for comparison of categorical variables. Crude incidence rates of the composite endpoint and its components were calculated per 100 person-years (PY). The overall crude incidence rate of the composite endpoint was also stratified according to CAD severity, which was a constructed ordinal variable: no significant stenosis, 1-, 2-, 3-VD, LMS, missing data on CAD severity or if no CAG. The 1-year (from day 7 until day 365 after discharge) and beyond (from day 366 until end of study) cumulative incidence curves for the composite endpoint according to CAD severity were estimated using the Nelson-Aalen estimator that account for the competing event of death from non-cardiovascular causes. Logistic regression and Cox proportional-hazards models were used to estimate the 1-year and beyond impact of CAD severity and co-morbidity on the composite endpoint, respectively. The models were adjusted for potential confounders, which included age, age groups, sex, calendar year, revascularization status, medication and socioeconomic status (income and civil status). No significant stenosis, the age group of 50-59 years, highest yearly income and married as civil status served as reference groups for the analyses. Patients with missing data on CAD severity (around 8%) were excluded in the logistic regression and Cox proportional-hazard models (complete case analyses). Three sensitivity analyses of the 1-year and beyond impact of CAD severity and co-morbidity on composite endpoint were conducted with stepwise exclusion of: (i) those with missing information on CAD; (ii) those with index MI in year 2010 because of disproportionately high occurrence of missing information on CAD severity; and (iii) those who did not receive CAG. The proportional hazard assumption, linearity of continuous variable, and lack of interaction were found to be valid unless otherwise indicated. All statistical analyses and data management were carried out using SAS, version 9.4 (SAS Institute, Cary, NC, USA) and R statistic software (version 3.1.1). P-values less than 0.05 were considered statistically significant.
Ethics
Register-based studies do not require ethical approval according to 
Study populations
During the study period, January 2004 to December 2010, 68 096 MI patients aged 18 years or older were hospitalized, of whom 55 747 (81.9%) patients survived and did not experience a recurrent MI or stroke 7 days after hospital discharge and were included in the study.
Of the MI population, 43 045 patients (77.2%) survived 365 days without any subsequent MI or stroke and were classified as the stable post-MI population with a mean duration of follow-up time of 3.6 years and maximum follow-up time of 9 years ( Figure 1 and Table 1 ).
Irrespective of study population, when stratified according to CAD severity, age, and co-morbidity burden increased with increasing CAD severity, but at the same time, the proportion of revascularized and treatment with P2Y 12 inhibitors declined as opposed to Tables S2  and S3) . Furthermore, utilization of CAG, revascularization, and P2Y 12 inhibitors increased as opposed to nitrates over the course of time. Patients enrolled in the early period were older and had more prevalent cardiac co-morbidities (MI and heart failure) (see Supplementary material online, Tables S4 and S5). (Table 4 and Supplementary material online, Table S6 ). The incidence rate of the primary composite endpoint increased with increasing CAD severity but was highest in patients who did not receive CAG. Similarly, the cumulative risk of primary composite endpoint the first 365 days post-index MI rose from 8.4% (7.6-9.2) in those with no significant stenosis to 26.4% (24.3-28.6 ) in those with LMS ( Figure 2A and CAD severity was the most important risk factor in relation to comorbidity ( Figure 3A) . Other important risk factors were increasing age, male gender, cerebrovascular disease, peripheral artery disease, shock, not receiving revascularization, not receiving secondary preventive medication (b-blockers, statin, aspirin, and P2Y 12 inhibitors) and use of nitrates (Supplementary material online, Figure S1 ).
Myocardial infarction population
Stable post-myocardial infarction population
Among the almost 82% of the stable post-MI patients that received CAG, 38.5% had MVD. Until study completion 9338 (non-fatal MI, 38.9%; non-fatal stroke, 17.9%; cardiovascular death, 43.2%) experienced a composite endpoint event (6.1/100 PYs; 95% CI, 5.9-6.2) ( Table 4 and Supplementary material online, Table S6 ). A similar trend was noted here. The incidence rate of the primary composite endpoint increased with increasing CAD severity, but was highest in patients who did not receive CAG. Similarly, the cumulative incidence of the composite endpoints at 4 years follow-up after becoming stable was overall 21.0% (20.6-21.4), but 13.6% (12.5-14.8) in patients with no significant stenosis and 25.2% (22.5-27.8) in patients with LMS (Table 4 and Figure 2B ). For patients who did not receive invasive examination, the risk was higher (41.0%, 39.8-42.1). After adjusting for confounders, CAD severity remained as the most important risk factor, but its relative importance in relation to comorbidity was less pronounced ( Figure 3B) . Additionally, important risk factors were increasing age, male gender, cerebrovascular disease, peripheral artery disease, heart failure, not receiving revascularization, not receiving statins and use of nitrates (Supplementary material online, Figure S2 ).
Sensitivity analysis
To test the robustness of our results, stepwise sensitivity analyses were carried out for both study populations. Excluding patients with missing information showed no changes for the risk of events. Data from the DHR in 2010 showed a higher proportion of missing data than in the preceding years ( 
Discussion
In this nationwide cohort study, encompassing almost 56 000 MI patients with a follow-up period of up to 9 years, we examined the risk of recurrent cardiovascular events (non-fatal MI, non-fatal stroke or cardiovascular death) in 2 distinct study populations. The key findings were: (i) one in five patients experienced a recurrent cardiovascular event the first 365 days, but for patients surviving the first 365 days without a recurrent cardiovascular event after MI, the risk remained equally high, with one in five patients experiencing an event later; (ii) CAD severity remained as the most critical factor for recurrent cadiovascular events both before and after the first 365 days; (iii) co-morbidity was a strong risk factor for cardiovascular events, but its relative importance was more pronounced in the long term. The findings from this present study add valuable knowledge to the limited evidence on impact of CAD severity on recurrent events in a nationwide post-MI cohort who had been stable for at least 1 year. Using CAD severity, which is a well-established risk factor for cardiovascular events to identify high-risk patients, we found a doseresponse relationship, but since CAD severity had been modified by important factors such as revascularization and pharmacotherapy at baseline, which differed across CAD severity, we did not measure the true effect of CAD severity. Furthermore, patients with no significant stenosis and to a certain extent those conservatively treated probably had a different underlying cause for MI, 22 
Prevalence of multi-vessel disease
In this present nationwide study on MI with a small percentage of non-naïve patients, the prevalence of MVD (2-VD or higher) among CAG recipients was about 41%. This is consistent with a previous Danish study on first-time MI. 32 Another study, with an almost similar setup to our study, reported a nearly identical prevalence of MVD (38%) in the index MI, 4 and as expected, a lower prevalence of 30%
was reported when only focusing on 3-VD, LMS, and prior CABG. The ICD-10 classification system does not account for the different subtypes of MI. Current evidence suggests that type 1 MI [traditionally corresponding to ST-segment elevation (STEMI) and non-ST-segment elevation (NSTEMI)] constitutes the largest group. 33 In STEMI and NSTEMI studies, MVD counts for around 50%. [34] [35] [36] Although Figure 3 Multivariable analyses showing the impact of CAD severity and co-morbidity on composite endpoint event in the index myocardial infarction population (A) and stable post-myocardial infarction population (B). The multivariable analysis is based on a complete case approach and adjusted for age, age-groups, gender, calendar year, revascularization, pharmacotherapy, and socioeconomic status. OR, odds ratio; HR, hazard ratio; CI, confidence interval; CAD, coronary artery disease; VD, vessel disease; CAG, coronary angiography; LMS, left main stenosis; MI, myocardial infarction; COPD, chronic obstructive pulmonary disease.
almost 39% had MVD in the stable post-MI population in the present study, others have reported in the range of 34-58%, 37-39 reflecting important differences in how their stable populations were selected. Altogether, the prevalence of MVD in MI and stable post-MI is comparable with national and international findings, but more importantly, this shows that a large proportion of MI patients surviving the first year without events had a high coronary atherosclerotic burden. Furthermore, we showed in both populations that age and comorbidity burden increased with increasing CAD severity, which is in line with other studies. 3, [39] [40] [41] As expected, we found that MI patients being event-free on the first year had a more favourable risk profile (younger, lower proportion of MVD and less degree of prior MI and stroke), an observation also made by others. 5 On that note, a considerable proportion of MI did not receive CAG. These patients were older and most likely had a higher occurrence of MVD, which in turn means that the true number of MVD was probably underestimated. Nevertheless, the complexity of MVD patients underscores the need for a coordinated effort involving optimal treatment of CAD along with appropriate management of significant co-morbidities. The importance of this is emphasized further by the expected increasing prevalence of CAD combined with the high and increasing burden of co-morbidity, 1 leading ultimately to an increasing economic burden on the health-care system.
Cardiovascular risk and risk factors
We demonstrated a considerable residual risk for cardiovascular events during the first year and the first 4 years of follow-up after becoming stable post-MI. More precisely, one out of 5 MI survivors experienced an event the first year and the same risk was observed after 4 years in stable post-MI patients. Studies on long-term prognosis have used different approach to identify high-risk patients. [4] [5] [6] Similar to the post hoc study on the PLATelet inhibition and patient Outcomes study (PLATO), 3 we focused on CAD severity, which, apart from being the best marker for coronary atherosclerosis burden, indirectly reflects the comorbidity burden. Thus, the study 3 found a 1-year risk of 16.3% when having MVD (defined as 3-VD, LMS or prior CABG), and a study 6 restricted to health insurance beneficiaries demonstrated an almost 21% risk after 4 years in high-risk (defined as DM, prior MI or/and chronic end stage kidney disease) stable post-MI patients. When focusing on overall estimates, a recent nationwide Swedish study 5 reported, similarly to our study, an 18.3% risk on the first year but a higher risk in the stable post-MI population (20% after 3 years vs. 21% after 4 years). This latter difference might reflect the fact that we, as opposed to Jernberg et al., 5 excluded high-risk patients (non-fatal CV events) at baseline. In a Spanish study, the corresponding estimates after 1 and 4 years were 7.3% and 10.1%, respectively. 4 These lower estimates might be expected in single-centre studies with higher rate of revascularization and with a closer clinical follow-up program. Nevertheless, we showed a relatively high residual risk and that the risk increased with increasing CAD severity not only during the first year (8.4-26.4%) but also in the successive years (13.6-25.2%). More importantly, those treated non-invasively had the highest risk (35.5% and 41.0%), as reported elsewhere. 7, 35, 42, 43 However, after adjusting for confounders including those related to type 2 MI, MVD appeared as the most important risk factor for cardiovascular events at 1-year and beyond. This is supported by 1-year-and partially by longer follow-up studies. 3, 4, 38 Similar to others, 4 we showed that the relative importance of MVD was greater in the first year than in the following years. At the same time, the importance of co-morbidity in relation to MVD was more pronounced in the stable post-MI population, which is in line with other studies. 4, 38 It is important to bear in mind that some co-morbidities (e.g., cerebrovascular disease and peripheral artery disease) share the same risk factor as for CAD, and in general, the extent of atherosclerosis in the coronary and non-coronary beds is a strong determinant of long-term prognosis. 44 This suggests that the impact of factors other than MVD becomes more important during long-term follow-up after the CAD has stabilized.
Follow-up and secondary prevention
We showed a slightly lower degree of initiation of secondary preventive drugs (b-blockers, aspirin P2Y 12 inhibitors and statins) and utilization of invasive strategy in MI as compared to other national studies. 7, 32 The most likely reason for this difference lies in the shorter period for initiating the medication and recording the invasive procedures. Similar to other studies from abroad, the majority received evidence-based therapies for CAD at baseline 4,5 and remained on it in the stable post-MI population. 5 Although there have been improvements in initiating secondary preventive drugs, a large group of MI patients faced undertreatment (primarily in nonobstructive CAD and conservative strategy) as reported elsewhere 45 ; thus, initiating medication at discharge is a critical factor for medication adherence. 46 Performing CAG is another critical factor that plays a part in the initiation of secondary prevention drugs. 7, 47, 48 A significant proportion of both study populations were assigned a conservative strategy, a proportion similar to other studies on MI and stable CAD. 32, 35, 37, 42, 47, 48 With increasing CAD severity, the rate of revascularization dropped and the prevalence of nitrates increased, and for those selected for a conservative strategy, a less aggressive treatment was given. As in previous studies, 7, 42, 43 these patients also appeared to be older and with greatest co-morbidity burden, crucial factors that are usually considered in the risk benefit analysis of an invasive strategy. 47, 48 While some found conservative strategy as being clinically justifiable, 47 others showed that the risk profile has been underestimated, 49 indicating a risk-treatment mismatch where high-risk patients have a lower likelihood to receive CAG, 40, 42 even though the benefit of an invasive strategy increases with baseline risk. 50 In this present study, we showed that the residual risk in stable post-MI patients with MVD was increased even though we adjusted for treatment. This indicates that selected patients might benefit from individualized treatment. That said, we also need to be better to achieve our treatment goals, as a large share of patients received suboptimal secondary prevention drugs (more pronounced in stable post-MI), invasive strategy (more pronounced in index MI) and according to the Euroaspire survey III do not enter cardiac rehabilitation programs after discharge. 8 
Special consideration of myocardial infarction subgroups
Special attention should be made to patients with no significant stenosis and conservatively treated patients, as their underlying cause for MI is different from obstructive CAD. 22, 31 Both represent the Coronary artery disease severity and long-term cardiovascular risk in MI patients opposite ends of the risk spectrum. As outlined above, the high risk associated with conservative strategy is understandable. Similarly, although the risk is lower in patients with no significant stenosis compared to those with more extensive CAD, it is still high and might be linked to undertreatment as well, 41 which is in line with our results.
More importantly, for both populations, there is no clear evidence of appropriate treatment recommendations even though these patients are not rare in clinical practice.
Limitations
The strength of this study lies in the large nationwide register-based cohort design, which provided a national study population on MI with close to complete information on CAD severity (8% missing) among CAD recipients and long-term follow-up data. A number of limitations inherent to the nature of retrospective studies are present. First, given that the positive predictive of the diagnosis for MI has been found high, 51 it was not possible to differentiate among STEMI, NSTEMI, and type 2 MI, which is a subgroup with emerging interest. Thus, the case mix of MI patients affect the generalizability of the study results, as STEMI and NSTEMI have different risk/prognosis. Second, in 2010, the DHR changed its data structure, and therefore, some variables had missing data, including for the CAD severity for 2010. We believe the information on CAD severity was missing at random. Another important point is that the DHR has national coverage on CAG only from 2006, which meant that a higher proportion of CAG without information on CAD (obtained from the DNPR) was noted in the preceding years. Sensitivity analyses showed no significant changes in the main results, other than an almost 7% point reduction in the overall cumulative incidence noted in both groups when conservatively treated patients were excluded. Third, some patients with LMS had evidence of 2-or 3-VD, giving them a more different risk profile. Furthermore, the estimation of CAD severity relied on the basis of the number of coronary vessels with a stenosis more than 50%, which is somehow less informative than such as the Syntax score, which was not registered in the DHR. Fourth, regardless of the number of CAG performed during index hospitalization, patients with different findings on the angiogram were categorized according to the most severe CAD severity. Fifth, during the study years, the implementation of high-sensitive assays most likely, to a certain extent, resulted in reclassification of unstable angina pectoris to NSTEMI, which meant that certain NSTEMI might have had a lower risk than NSTEMI in the preceding period. Finally, there is a lack of information about important clinical parameters such as complete vs. incomplete revascularization, fibrinolytic agents, left ventricular ejection fraction, infarct size, blood pressure, body mass index, lipid levels, and cardiac rehabilitation programs. Thus, we were unable to account for achievement of treatment goals, and therefore, we cannot rule out the effect of unmeasured confounders while estimating the effect of CAD severity and co-morbidity.
Conclusions
This nationwide study showed that stable post-MI patients had increased risk of cardiovascular events beyond the first year and was strongly related to CAD severity. Despite medical treatment and that a large part of patients with multi-vessel disease underwent revascularization, CAD severity was the strongest risk factor for recurrent cardiovascular event in a long-term perspective.
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